Clinical Trials Logo

Cicatricial Alopecia clinical trials

View clinical trials related to Cicatricial Alopecia.

Filter by:
  • None
  • Page 1

NCT ID: NCT05549934 Recruiting - Clinical trials for Cicatricial Alopecia

Ritlecitinib for Cicatricial Alopecia

Start date: December 15, 2022
Phase: Phase 2
Study type: Interventional

Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known as cicatricial alopecia (CA), in which hair follicles are irreversibly destroyed. CA leads to scarred areas, most commonly on the scalp, that cannot re-grow hair. Despite being a long-term condition, that often has significant impact on patients' well-being, available effective treatments for these diseases are lacking. In addition, the molecular abnormalities causing CA are largely unknown. The research team will be administering a new investigational drug (a JAK3/TEC inhibitor), ritlecitinib, which has shown statistically significant improvement in scalp hair loss for AA patients in a proof of concept and phase 2b/3 studies (B7981015 AA study). This is an open-label clinical trial. CA patients will be asked to provide small samples of skin and blood throughout the treatment period, to find out how they respond to the drug, and to attempt to better understand these diseases.

NCT ID: NCT05076006 Completed - Clinical trials for Cicatricial Alopecia

Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia

Start date: May 19, 2021
Phase: Phase 2
Study type: Interventional

Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known as cicatricial alopecia (CA), in which hair follicles are irreversibly destroyed. CA leads to scarred areas, most commonly on the scalp, that cannot re-grow hair. Despite being a long-term condition, that often has significant impact on patients' well-being, available effective treatments for these diseases are lacking. In addition, the molecular abnormalities causing CA are largely unknown. The study team's research involves administrating patients a new investigational drug (a combined TYK/JAK inhibitor) which has been shown to be safe and well tolerated in clinical studies to date, and is being investigated in other conditions, such as AA. CA patients will be asked to provide small samples of skin and blood throughout the treatment period, to find out how they respond to the drug, and to attempt to better understand these diseases.

NCT ID: NCT04472715 Completed - Clinical trials for Cicatricial Alopecia

Hair Transplantation in Cicatricial Alopecia

Start date: January 5, 2020
Phase: N/A
Study type: Interventional

follicular unit extraction as a method of hair transplantation in cicatricial alopecia